Buda Juice Begins Trading on NYSE American, Pioneering UltraFresh Juice Category

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Jan 08 2026

0mins

BUDA-2%

Should l Buy BUDA?

Source: Globenewswire

Listing Milestone: Buda Juice, Inc. commenced trading on the NYSE American on January 8, 2026, under the ticker symbol 'BUDA', marking its official entry into the fresh juice market and is expected to attract increased investor interest.
Innovative Product: The company offers UltraFresh™ juices through its cold chain platform, maintaining products at 35°F with an 8 to 12-day shelf life, significantly enhancing product quality for retailers and improving consumer experience.
Market Expansion: Buda Juice is expanding its branded portfolio, entering new geographic markets and scaling a growing white-label platform that provides significant cost savings and fresh product differentiation for retail customers, enhancing competitive positioning.
Strategic Advantage: By offering ready-to-drink juice solutions without the need for additional infrastructure, Buda Juice not only meets consumer demand for fresh beverages but also simplifies operational processes for retailers, thereby driving overall industry innovation.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BUDA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BUDA

About BUDA

Buda Juice, Inc. operates in a beverage industry, focused on UltraFresh juice-offering cold-crafted citrus-based drinks. The Company offers an end-to-end cold chain platform that always delivers cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. Its product portfolio consists of fresh citrus juice, a fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using its cold chain process. Its products include Buda Juice (Organic), Buda Fresh - Value-Forward Offering (Non-Organic), and Private Label Products (Non-organic and Organic). Buda Fresh includes Fresh 12 oz Lime Juice, 16 oz and 128 oz Lemon Juice, Fresh Orange and Grapefruit Juice (16 oz, 32 oz and 52 oz), and Fresh Citrus-based Lemonades and Limeades (16 oz and 52 oz). Private Label Products include Fresh Citrus Line (52 oz) and Fresh Citrus-based Lemonades and Limeades (52 oz).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Buda Juice Reports Strong FY Results with $12.61M Revenue

4 days agoseekingalpha

Financial Highlights: Buda Juice, Inc. reported a FY GAAP EPS of $0.20 and revenue of $12.61 million, reflecting an 11.9% year-over-year growth, indicating strong performance and growth potential in the cold chain market.
Adjusted EBITDA: The company reported an adjusted EBITDA of $3.8 million, showcasing improved operational efficiency, which enhances investor confidence in its profitability.
Free Cash Flow: Buda Juice generated free cash flow of $3.0 million, demonstrating robust capital management that provides ample funding for future expansion and investments.
IPO Expectations: Buda Juice priced its initial public offering at $20 million, with positive market response, which is expected to further boost the company's market share and brand influence in the cold chain industry.

2026 IPO Market Starts Steadily with $2.6 Billion Raised

Feb 04 2026renaissancecapital

IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, although a backlog of startups indicated IPO plans, the overall deal count and proceeds fell below the ten-year average, reflecting cautious market sentiment.
Sector Dynamics: The industrial sector's EquipmentShare.com led with $747 million raised, surging 33% on its first day, indicating strong investor demand for fast-growing companies viewed as resistant to AI disruption.
SPAC Issuance Surge: January saw SPAC issuance reach a four-year high with 25 blank check deals raising $5.2 billion, providing hundreds of pre-IPO companies with an alternative path to public markets, reflecting growing interest in emerging technology firms.
Active IPO Pipeline: By the end of January, the IPO pipeline included 216 companies seeking to raise approximately $12.4 billion, with 130 having filed or updated within the last 90 days, demonstrating ongoing market interest in new public offerings.

2026 IPO Market Starts Steadily with $2.6 Billion Raised

Feb 04 2026renaissancecapital

IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, reflecting a cautious market sentiment as this figure fell short of the ten-year average, particularly after the volatility experienced in Q4 2025.
Sector Dynamics: The industrial sector led the month’s largest IPOs, with EquipmentShare.com raising $747 million, highlighting investor preference for fast-growing companies perceived as resilient to AI disruption.
Emerging Trends: The fintech and biotech sectors showed signs of recovery at the start of 2026, notably with fintech PicPay becoming the first Brazilian IPO in four years, raising $434 million, although its shares fell 5% post-IPO.
SPAC Activity: January saw SPAC issuance reach a four-year high with 25 deals raising $5.2 billion, indicating growing interest in pre-IPO companies opting for SPAC mergers, despite overall IPO activity remaining below 2021 peaks.

Aktis Oncology Prices Upsized IPO at $318 Million, Targets Solid Tumors

Jan 10 2026renaissancecapital

Successful Financing: Aktis Oncology priced its upsized IPO at $318 million, achieving a market cap of $1 billion, marking the first significant deal of 2026 and demonstrating strong market interest in its radiopharmaceuticals targeting solid tumors.
Technological Edge: The company's alpha-emitting radiopharmaceuticals have shown superior efficacy in preclinical studies compared to Padcev, although it faces risks due to its early-stage pipeline, yet its unique treatment approach may attract investor attention.
Market Performance: Aktis saw a 24% increase in its stock price during its first week of trading, reflecting investor recognition of its potential market value and providing a solid foundation for future financing and R&D efforts.
Industry Outlook: With the rising demand for targeted therapies, Aktis's successful IPO not only enhances its visibility in the biotech sector but may also stimulate financing activities for similar companies, fostering growth across the industry.